Last reviewed · How we verify
SD in Subjects With T2DM
This study will assess the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and pharmacodynamics (explores what a drug does to the body) of JNJ-38431055 in volunteers with type 2 diabetes mellitus.
Details
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 25 |
| Start date | 2009-04 |
| Completion | 2009-07 |
Conditions
- Diabetes Mellitus, Type 2
Interventions
- JNJ-38431055 Dose 1
- Sitagliptin 100 mg
- Placebo
- JNJ-38431055 Dose 2
Primary outcomes
- Incremental glucose AUC after an oral glucose tolerance test (OGTT) — 0-4 hours after OGTT
Countries
United States